FDA APPROVES OF A NEW NASAL SPRAY GIMOTI
The new nasal spray will be useful in relieving patents of diabetic gastroparesis
The commercial launch shall be in Q4 2020
Evoke Pharma Inc’s nasal spray GIMOTI is now approved by the Food and Drug Administration, USA. This was announced by the company on Friday via SEC filing.
GIMOTI is a nas....
Tags : FDA, diabetic gastroparesisc, Evoke Pharma Inc.GIMOTI, Eversana Life Services. ,